|
|
|
51-200 employees
View all
|
|
biotechnology
|
|
4233 Technology Drive,Durham,North Carolina,US
|
|
Argos Therapeutics is an immuno-oncology company focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases using its ArcelisĀ® technology platform. Argos' most advanced product candidate, rocapuldencel-T, is being evaluated in the pivotal ADAPT Phase 3 clinical trial for the treatment of metastatic renal cell carcinoma (mRCC). In addition, rocapuldencel-T is being studied in Phase 2 investigator-initiated clinical trials as neoadjuvant therapy for renal cell carcinoma (RCC) and for the treatment of non-small cell lung cancer (NSCLC). Argos is also developing a separate ArcelisĀ®-based product candidate, AGS-004, for the treatment of human immunodeficiency virus (HIV), which is currently being evaluated in an investigator-initiated Phase 2 clinical trial aimed at HIV eradication in adult patients.
|
Argos Therapeutics, Inc. (NASDAQ: ARGS) Email Formats | Example Email Formats | Percentage |
---|---|---|
{f}{last} | [email protected] |
75%
|
The widely used Argos Therapeutics, Inc. (NASDAQ: ARGS) email format is {f}{last} (e.g. [email protected]) with 75% adoption across the company.
To contact Argos Therapeutics, Inc. (NASDAQ: ARGS) customer service number in your country click here to find.
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.